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Abstract 
Malignant transformation of cells is associated with aberrant glycosylation presented on the cell-
surface. Commonly observed changes in glycan structures during malignancy encompass 
aberrant expression and glycosylation of mucins; abnormal branching of N-glycans; and 
increased presence of sialic acid on proteins and glycolipids. Accumulating evidence supports the 
notion that the presence of certain glycan structures correlates with cancer progression by 
affecting tumor cell invasiveness, ability to disseminate through the blood circulation and to 
metastasize in distant organs. During metastasis tumor cell-derived glycans enable binding to 
cells in their microenvironment including endothelium and blood constituents through glycan-
binding receptors - lectins. In this review we will discuss current concepts how tumor cell-
derived glycans contribute to metastasis with the focus on three types of lectins: siglecs, galectins 
and selectins. Siglecs are present on virtually all hematopoietic cells and usually negatively 
regulate immune responses. Galectins are mostly expressed by tumor cells and support tumor cell 
survival. Selectins are vascular adhesion receptors that promote tumor cell dissemination. All 
lectins facilitate interactions within the tumor microenvironment and thereby promote cancer 
progression. The identification of mechanisms how tumor glycans contribute to metastasis may 
help to improve diagnosis, prognosis and aid to develop clinical strategies to prevent metastasis.  
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Introduction  
The majority of cancer deaths are attributed to the metastatic spread of cancer cells to vital organs 
rather than to the primary tumor outgrowth. During malignant transformation the genetic 
alteration in the cells results in mutations of proto-oncogenes and tumor suppressor genes, which 
as a result give rise to tumor clones with different properties (Hanahan and Weinberg, 2011). 
Malignant cells thereby acquire characteristics enabling them dissociation from tumors, 
degradation of the extracellular matrix, invasion, adhesion and metastasis to distant organs. 
Alteration of tumor cell-surface glycosylation is one of the characteristic traits associated with 
enhanced malignancy (Hakomori, 1985, Kannagi, 1997, Kim and Varki, 1997). Glycans are 
oligosaccharide structures that are covalently bound to proteins, lipids or present in a free form in 
tissues or tumors. Glycans are bound to the protein either through Asn (N-linked glycan) or 
through Ser or Thr (O-linked glycan). Lectins are a family of carbohydrate-binding proteins that 
specifically recognize glycans. Fundamental processes such as cell-cell recognition, cell 
adhesion, mobility and pathogen-host interaction are facilitated by lectins in healthy organisms. 
The common expression of lectins on endothelial cells, immune cells, in the extracellular matrix 
or as soluble adhesion molecules enables them to bind to tumor cell glycans and thereby affect 
tumor cell progression (Fuster and Esko, 2005). Subsequently, accumulating evidence supports 
the involvement of tumor cell-surface glycans in tumor cell migration, adhesion and metastasis. 
This review addresses the role of cancer-associated glycans during metastasis with the focus on 
endogenous lectin interactions within the tumor microenvironment.  
The process of metastasis 
Hematogenous metastasis is a multistep process during which malignant cells detach from the 
primary tumors, degrade the extracellular matrix, invade the surrounding tissue, enter the blood 
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or lymphatic vessels, and extravasate to form metastatic lesions. Tumor cells through the cell-
surface glycans can engage with a variety of endogenous lectins both at the primary site of a 
tumor and in the circulation. Tumor cell upon reaching the blood circulation induces 
microthrombi, the formation of which is facilitated by platelet P-selectin binding to tumor cell 
surface glycans (Kim et al., 1998, Varki, 2007). Tumor cell emboli formation contributes to 
mechanical lodging in the microvasculature and/or adhesion to the endothelium thereby 
promoting tumor cell extravasation and metastasis (Labelle and Hynes, 2012). There is 
accumulating evidence that vascular lectins – selectins facilitate tumor cell interactions with all 
blood constituents, platelets, leukocytes, and endothelial cells, and thereby contribute to 
metastasis (Kannagi, 1997, Läubli and Borsig, 2010, Witz, 2008). In addition, recruitment of 
immune cells to the metastatic microenvironment is dependent on selectins (Borsig et al., 2002, 
Hoos et al., 2013, Läubli et al., 2006).  
Specific glycan structures on colonic epithelium provide immune-modulatory activity to tissue 
macrophages through sialic acid binding lectins - siglecs (Belisle et al., 2010, Miyazaki et al., 
2012). In addition, galactose-binding lectins – galectins were shown to be involved in immune-
suppression and metastasis (Ito et al., 2012). Consequently, altered glycosylation may both 
induce inflammatory reactions and promote immune-suppression, however; it is dependent on the 
cellular context within the tissue. Finally, glycan changes associated with cancer progression 
profoundly define the phenotype of cancer cells depending on interactions with endogenous 
lectins both in tumor and metastatic environments.  
 
General mechanisms for altered glycosylation in cancer 
Cancer progression requires a range of alterations in extracellular and intercellular signaling that 
promotes cell proliferation, emergence of invasive subsets, dissociation from the tumor, 
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intravasation and adhesive interactions within the circulation that finally facilitate metastasis. 
Within the tumor environment changes in glycosylation allow malignant cells to promote cell 
mobility, cell adhesion and even receptor activation, and thereby contributing to the invasive 
phenotype (Fuster and Esko, 2005, Kannagi, 1997, Kim and Varki, 1997). Malignant 
transformation leads to expression of oncofetal antigens, epitopes that are present on embryonic 
tissues and tumor cells, but are generally absent in healthy adult cells. Neo-synthesis and 
incomplete synthesis are the two major mechanisms for generation of cancer-specific glycans 
(Hakomori, 1985).  
Altered glycosylation of N-linked glycans in cancer is typically associated with enhanced β1,6-
branching that is facilitated by β1,6-N-acetylglucosaminyltransferase-5 (GnT5) (Dennis et al., 
1987, Lau and Dennis, 2008). Increased activity of GnT5 is associated with increased 
polylactosaminic sequences, and the inhibition of GnT5 resulted in attenuation of metastasis 
(Guo et al., 2007, Lagana et al., 2006). GnT5 deficiency (Mgat5-deficient mice) resulted in 
reduced tumor growth and metastasis (Granovsky et al., 2000). However, the functional role of 
branched N-glycosylation in cancer was later shown to be dependent on galectin binding and 
thereby altering the phenotype of the cell (Partridge et al., 2004).  
Virtually in every cancer type upregulation of glycosyltransferases has been detected, leading to 
expression of common tumor cell epitopes such sialyl-Lewisx and sialyl-Lewisa (sLex/sLea), 
Thomsen-nouvelle antigen (Tn) and sialyl-Tn (sTn) (Borsig, 2011, Fuster and Esko, 2005, 
Kannagi, 1997, Kaur et al., 2013, Kim and Varki, 1997). Hypoxia has been identified as one of 
the factors leading to increased expression of glycosyltransferases (Dall'Olio et al., 2012, 
Kannagi et al., 2010). For instance, increased expression of α1,3-fucosyltransferase-7 (FUT7) 
and α2,3-sialyltransferase ST3Gal1, enzymes involved in synthesis of sLex/a has been detected 
(Koike et al., 2004). The general increase in sialylation has been detected both in clinical settings 
5 
 
and experimental models that is associated with a metastatic cell phenotype (Dall'Olio et al., 
2012, Schultz et al., 2012, Varki and Varki, 2007). An increase in α2,6-sialylation in tumors is 
usually attributed to the upregulation of ST6Gal1 sialyltransferase that is primarily active on N-
linked glycans (Dall'Olio et al., 1989, Gessner et al., 1993, Seales et al., 2005), or ST6GalNAc 
family of sialyltransferases which are active on O-linked glycans or glycolipids (Marcos et al., 
2011). Accordingly, overexpression of Neu1 sialidase in colon cancer cells led to reduced liver 
metastasis in mice due to increased desialylation of β4integrin whereas silencing of Neu1 
sialidase increased cell migration, invasion and adhesion in vitro (Uemura et al., 2009). 
Synthesis of shorter glycan structures like Thomsen-Friedenreich (TF or T), Tn and -sTn epitopes 
has been observed in a number of carcinomas (Baldus et al., 2002, Campbell et al., 1995, Kumar 
et al., 2005, Sotozono et al., 1994, Springer, 1984). One of the factors affecting the synthesis of 
incomplete glycan structures is the frequent mutation of the Cosmc chaperone that is required for 
the galactosyltransferase activity that modifies O-linked glycans (Ju et al., 2008). Another 
example of shortened glycan synthesis is the reduced expression of disialyl-Lewisa (di-sLea) and 
sialyl 6-sulfo Lewisx structures in epithelial cancer. Disialyl-Lewisx (di-sLex) structure is 
synthesized with the α2,6-sialyltransferase ST6GalNAc6, and its expression is downregulated by 
epigenetic silencing in malignant epithelium (Miyazaki et al., 2004, Tsuchida et al., 2003). 
Similarly, repressed expression of sulfotransferase responsible for 6-sulfo Lex was detected in 
cancer cells but not in normal epithelial cells (Kannagi et al., 2010).  
Gangliosides are sialic acid-containing glycolipids, which expression is often disregulated during 
malignant transformation (Hakomori, 1985). Apart from glycolipid specific glycan structures 
containing disialic acid in a α2,8-linkage (e.g. GD3), changes in glycosyltransferases promote 
expression of sLex epitopes (Nudelman et al., 1986). Overexpression of sialidase Neu2 led to 
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reduced metastasis, while Neu2 was found to be downregulated in highly metastatic variants of 
colon carcinoma (Sawada et al., 2002). 
Despite many possibilities how glycans can be formed (linkage and sequence of monosaccharide 
units) there is a rather small number of structures commonly detected in cancer. Furthermore, 
terminal glycan structures exposed on the cell surfaces of tumor cells can be recognized through 
endogenous lectins and thereby modulate cancer progression.   
 
Alterations of cancer associated O-linked glycans 
Mucins are high molecular weight glycoproteins exhibiting a rod like conformation due to heavy 
glycosylation with O-linked glycans (Hollingsworth and Swanson, 2004, Kannagi, 1997). O-
linked glycosylation, which is based on GalNAc bound to the Ser/Thr of a protein, is further 
modified by galactose (core 1 structure) or GlcNAc (core 3 structure) in normal mucins (Figure 
1). During malignant transformation mucins of intestine, colon, liver and pancreas have reduced 
core 1 and core 3 structures that correlate with enhanced sialylation of Tn and T antigens 
(Brockhausen, 2006, Kaur et al., 2013, Taylor-Papadimitriou et al., 1999). Core 3-derived 
glycans are a major type expressed by normal epithelial cells of the gastrointestinal tract, which 
are downregulated during malignancy due to loss of functional β3-N-
acetylglucosaminyltransferase-6 (core 3 synthase) expression (Iwai et al., 2005, Radhakrishnan et 
al., 2013). On contrary, overexpression of core 3 synthase in pancreatic cells was associated with 
decreased presence of Tn antigens and resulted in a reduced tumorigenicity and metastasis upon 
orthotopic injection. In addition, enhanced expression of the core 2 β1,6-N-
acetylglucosaminyltransferase (C2GnT1) responsible for the core 2 synthesis was detected in 
colorectal and lung carcinomas which correlated with high levels of sLex on O-glycans and 
therefore strong binding to E-selectin and metastasis compared to normal tissues (Machida et al., 
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2001, Shimodaira et al., 1997, St Hill et al., 2009). Mucins of normal mammary epithelial cells 
contain a mixture of O-glycans and the majority is core 2-based structures (Brockhausen et al., 
1995, Burchell et al., 2001). Reduced expression of C2GnT1 in mammary cancer is associated 
with enhanced presence of Tn and sTn (Brockhausen et al., 1995, Burchell et al., 2001, Dalziel et 
al., 2001, Solatycka et al., 2012). However, despite reduced core 2 structures on breast cancer 
cells, increased presence of sLex epitopes has been observed, which likely is a result of increased 
fucosylation (Matsuura et al., 1998). 
 
Formation of T, Tn, and sTn antigens during cancer progression 
In healthy tissues core 1-based T and Tn epitopes are almost absent however; in about 90% of all 
human carcinomas these precursor structures are detected (Campbell et al., 1995, Springer, 
1984). Unsubstituted Tn epitopes occur in human cancers of colon, breast, bladder, prostate, 
liver, ovary and stomach; and their presence correlate with cancer progression and metastasis 
(Baldus et al., 2002, Campbell et al., 1995, Cao et al., 1996, Coon et al., 1982, Ghazizadeh et al., 
1990, Itzkowitz et al., 1989, Kumar et al., 2005, Limas and Lange, 1986, Zhang et al., 1997). 
Similarly, sialylated T and Tn antigens correlate with progression of epithelial cancer and poor 
clinical prognosis of many carcinomas (Dall'Olio et al., 2012, Davidson et al., 2000, Devine and 
McKenzie, 1992, Schultz et al., 2012, Springer, 1984, Yu, 2007). ST6GalNAc1-mediated α2,6-
linked sialylation of GalNAc of the precursor Tn antigen results in formation of the sTn antigen 
(Dall'Olio et al., 2012, Julien et al., 2001, Ozaki et al., 2012, Yang et al., 1994). The sialylation 
step prevents further glycan extension and therefore leads to truncation of O-linked glycans 
(Brockhausen, 1999, Taylor-Papadimitriou et al., 1999).  
Several mechanisms have been described to enable increased Tn, sTn or T expression in cancer 
(Table 1 and Brockhausen, 2006, Marcos et al., 2011). 1) Decreased activity of core 2 C2GnT1 
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enzyme leads to accumulation of T antigen (described above) that is further sialylated by 
ST6GalNAc1 and ST6GalNAc2 enzymes (Marcos et al., 2004, Schneider et al., 2001). 2) 
Enhanced availability of the nucleotide sugar substrate UDP-galactose appears to promote 
increased T antigen biosynthesis through core 1 β1,3-galactosyltransferase (Kumamoto et al., 
2001). Colon cancer tissues expressed increased levels of the UDP-Galactose transporter, which 
brings the sugar donor into the Golgi apparatus compared to non-malignant mucosa. 3) Activity 
of β1,3-galactosyltransferase (T synthase) requires the presence of the molecular chaperon 
protein Cosmc, which is responsible for folding and stability of the enzyme (Ju and Cummings, 
2002, Ju et al., 2008). The absence of Cosmc leads to β1,3-galactosyltransferase degradation. 
Mutation in Cosmc chaperone is associated with increased Tn expression in colon carcinoma and 
melanoma cell lines and also increased sTn expression (Ju et al., 2008, Schietinger et al., 2006). 
Accordingly, downregulation of T synthase resulted in a marked increase of T, Tn, and 
particularly sTn in colon carcinoma cells (Barrow et al., 2013). 4) Generation of sTn is facilitated 
by the sialyltransferase ST6GalNAc1 and ST6GalNAc2. (Marcos et al., 2004, Schneider et al., 
2001). Human gastric cancer cells with enhanced ST6GalNAc1 expression showed higher 
intraperitoneal metastasis compared to sTn-negative tumor cells. Similarly, overexpression of 
ST6GalNAc1, thereby sTn epitope, in human breast cancer cells led to increased tumor growth in 
immunodeficient mice (Julien et al., 2006, Ozaki et al., 2012). In addition, enhanced sialylation 
of T antigen in breast cancer correlated with higher levels of α2,3-sialyltransferase (ST3Gal1) 
(Burchell et al., 1999, Schneider et al., 2001). Overexpression of ST3Gal1 under the human 
MUC1 promoter in a spontaneous murine breast cancer model resulted in significantly decreased 
tumor latency compared to mice without ST3Gal1 overexpression (Picco et al., 2010). 
Furthermore, the sialyltransferase expression alone was responsible for enhanced tumorigenesis 
indicating that this enzyme per se acts as a tumor promoter (Picco et al., 2010). 
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Only few glycoproteins are known to present Tn, T or sTn and sialyl-T (sT) antigens in malignant 
tissues (Yu, 2007). Mucin MUC1 and CD44v6 display sTn and sT antigens in colon, gastric and 
breast cancers (Baldus et al., 1998, Burdick et al., 1997, Singh et al., 2001, Storr et al., 2008). 
MUC2 is a major carrier of shortened glycans in gastric cancer (Conze et al., 2010). Enhanced 
sTn expression in breast and gastric cancer is associated with overexpression of MUC1, CD44 
and ST6GalNAc1 (Julien et al., 2006, Ozaki et al., 2012). Although CD44v6 is expressed in some 
types of healthy epithelia, higher expression is observed in squamous cell carcinomas and 
adenocarcinomas including breast, lung, colon and pancreatic carcinomas (Hofmann et al., 1991, 
Ponta et al., 2003, Wai and Kuo, 2004). Interestingly, serum levels of osteopontin, a CD44 
ligand, that itself is a sTn carrier, have been detected in cancer patients and correlate with bad 
prognosis (Wai and Kuo, 2004).  The enhanced expression of Tn, sTn and T antigens on MUC1, osteopontin and CD44 is associated with high metastatic potential and poor prognosis (Bresalier et al., 1991, Conze et al., 2010, Nakamori et al., 1993). However, there is little evidence for the functional consequence of this aberrant glycosylation during cancer progression. In human breast cancer cells, expression of sTn on MUC1 was associated with reduced cell adhesion and increased cell migration (Julien et al., 2006). In addition, β1 integrins carry aberrant forms of 
O-glycans that is associated with metastasis (Clement et al., 2004). Enhanced expression of 
ST6GalNAc1 in murine carcinoma cells led to an increase in sTn expression on β1 integrin 
subunit associated with morphological changes including loss of epithelial appearance, 
disorganization of actin stress fibers and reduced ability to migrate on fibronectin. A recent study 
showed that high expression of the ppGalNAcT13, which initiates O-glycan synthesis by adding 
the first GalNAc to Ser/Thr, induced high metastatic potential of Lewis lung carcinoma by 
generating trimeric Tn antigens (GalNAc1-Ser/Thr)3 on syndecan 1 (Matsumoto et al., 2012). 
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The complex formation of trimeric Tn antigens on Syndecan 1 together with α5β1 integrin and 
MMP-9 resulted in enhanced invasion and metastasis. Recent findings provide evidence that cell-
surface mucins are involved in signal transduction events (reviewed in (Hollingsworth and 
Swanson, 2004, Kaur et al., 2013). Decreased sTn expression on neuroblastoma achieved by 
extension of core 1 structure with B3GNT3 expression reduced activation of focal adhesion 
kinase and thereby partially suppressed malignant phenotype (Ho et al., 2013). Aberrant 
glycosylation in cancer does not affect only the tumor cell phenotype behavior (e.g. proliferation, 
differentiation, adhesion), but also contribute to the control of the local microenvironment, 
immune responses and metastasis. Therefore these glycans serve as ligands for cells in the tumor 
microenvironment through endogenous lectins.    
Siglecs 
Sialic acid-binding immunoglobulin superfamily lectins (siglecs) are the largest family of sialic-
acid-binding molecules (Crocker et al., 2012, O'Reilly and Paulson, 2009, Varki and Gagneux, 
2012). Siglecs are expressed on specific subpopulations of hematopoietic cells where they exert 
their immune-regulatory function. Many siglecs contain intracellular tyrosine motifs which 
include one or more membrane-proximal immunoreceptor tyrosine-based inhibitory motif (ITIM) 
and a membrane-distal ITIM-like motif (Crocker et al., 2012, O'Reilly and Paulson, 2009). These 
motifs are involved in inhibitory signal transduction. Based on both sequence similarity and 
conservation between mammalian species siglecs are divided in two major subgroups. The first 
group comprises Siglec-1 (sialoadhesin, CD169), Siglec-2 (CD22), Siglec-4 (Myeloid-associated 
glycoprotein) and Siglec-15. The second subfamily of CD33/Siglec-3 related siglecs consists of 
10 human members (Siglec-3, -5, -6, -7, -8, -9, -10, -11, -14, -16) and 5 rodent members (Siglec-
3, -E, -F, -G, -H) (Crocker et al., 2012, Varki and Gagneux, 2012). The first subgroup with its 
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evolutionary conserved members has restricted expression patterns. For instance Siglec-1 is 
specifically expressed on macrophages, Siglec-2 on B-cells and Siglec-4 on oligodendrocytes and 
Schwann cells in the nervous system (Crocker et al., 2007). On the other hand CD33-related 
siglecs display a more divergent expression pattern dependent on developmental stage of immune 
cells (Crocker et al., 2012, Varki and Gagneux, 2012). The high sialic acid concentration on the 
cell surface of siglec-expressing cells often leads to binding to the cell glycans (in cis) or adjacent 
cells (in trans). Siglecs can be affected by various stimuli including cytokines, toll-like receptor 
activation, viral and bacterial infections the biology of siglecs is therefore rather complex 
(Crocker et al., 2007). The binding specificity of siglecs depends on the distinct types, linkages 
(α2,3, α2,6 and α2,8), arrangements of sialic acids, their way of presentation on different cells, 
organs and organisms. Siglec binding to ligands modulates cell-cell interactions, cell 
proliferation, cell death and endocytosis (Avril et al., 2006, Crocker et al., 2007, Lock et al., 
2004, Nutku et al., 2003).  
 
The role of siglecs in cancer progression 
Accumulating evidence indicates that the interaction between tumor-specific glycans and lectins 
on immune cells are involved in modulation of the tumor microenvironment (Rabinovich et al., 
2012). The inhibitory nature of siglec upon binding of specific glycan may lead to dampening of 
immune responses and thereby escape of immune surveillance and clearance. Whether siglecs 
contribute to cancer progression through recognition of distinct cancer-specific glycan structures 
is currently under investigation. Nonmalignant colon epithelial cells express disLea epitopes that 
serve as ligands for both Siglec-7 and -9 (Miyazaki et al., 2012). The expression of siglec ligands 
was decreased upon malignant transformation, which was associated with enhanced expression of 
sLex and sLea epitopes (Kannagi et al., 2010). Expression of ST6GalNAc6 which synthesizes 
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disLea in human colon cancer cells resulted in increased disLea, loss of sLea epitopes and 
increased binding to Siglec-7 (Miyazaki et al., 2004). Mainly resident macrophages were found 
to carry Siglec-7 and -9 in a colonic lamina propria and Siglec-7/9 ligation could suppress 
macrophage-mediated cyclooxygenase-2 (COX2) and prostaglandin E2 expression and thereby 
prevent inflammatory damage of the colonic mucosa (Miyazaki et al., 2012). Siglec-15, which 
preferentially recognizes sTn antigen, is expressed in tumor-associated macrophages (TAMs) in 
various human carcinoma tissues including lung, liver and rectum (Takamiya et al., 2013). 
Binding of myeloid cells through Siglec-15 to sTn on tumor cells resulted in increased TGF-β 
secretion into the tumor microenvironment that is associated with cancer progression. 
Interestingly, Siglec-15 expression was induced by M-CSF which usually polarized macrophages 
to M2 phenotype commonly detected in the tumor microenvironment.   
Siglec-1 is expressed in a subset of macrophages that are involved in the pathophysiology of 
cancer (Crocker and Gordon, 1986). Clinical observation showed that increased Siglec-1 is 
present in splenic marginal cell lymphoma as well as in macrophage infiltrates of MUC1-positive 
breast cancers (Marmey et al., 2006, Nath et al., 1999). Siglec-1 positive macrophages were 
found to infiltrate into rat xenograft tumors in a CCL2-dependent manner (Yamashiro et al., 
1994). On contrary, recent study demonstrated that Siglec-1 positive macrophages in regional 
lymph nodes of colorectal carcinoma patients promote CD8+ T-cell mediated anti-tumor 
immunity and are associated with a better prognosis for these patients (Ohnishi et al., 2013). 
Siglec-9, a surface receptor on NK cells, B cells and monocytes, has been identified as a receptor 
for mucin MUC16 (Belisle et al., 2010). Cell-surface bound as well as soluble MUC16 is 
overexpressed in human ovarian tumor cells and detected in peritoneal fluid of cancer patients 
(Buller et al., 1992). Engagement of Siglec-9 on monocytes also induced secretion of 
immunosuppressive cytokine IL-10 (Ando et al., 2008). Similar immune suppression mediated by 
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Siglec-7 on NK cells was observed in renal cell carcinoma expressing disialosyl 
globopentaosylceramide (DSGb5) as a major ganglioside (Kawasaki et al., 2010). Recent study 
from C. Bertozzi group provided strong evidence that siglec-7-mediated cytotoxicity of NK cells 
can be modulated by the presentation of glycans on cell surfaces (Hudak et al., 2014). 
Presentation of sialylated ligands on tumor cells recognized by siglec-7 resulted in enhanced 
phosphorylation of cytoplasmic tyrosine residues, causing dampening of cytolytic activity.   
The association between Siglec-9 positive immune cells and MUC1 positive tumor cells has been 
detected in tissues of human colon, pancreas and breast cancer. Interestingly, Siglec-9 binding to 
MUC1 expressing tumor cells was shown to induce recruitment of β-catenin in tumor cells 
resulting in promotion of cell growth in vitro (Tanida et al., 2013). These findings suggest that 
Siglec-9 engagement of carcinoma mucin MUC1 may be involved in tumor growth, however; the 
nature of Siglec-9 ligands as well as the cellular context in vivo remains to be defined.  
Taken together, the current evidence is largely based on clinical correlation of cancer-glycan 
expression and several experiments showing Siglec-cancer glycan interaction in vitro. Whether 
these interactions indeed functionally modulate immune cell responses in the tumor 
microenvironment and thereby affect cancer progression in vivo requires experimental validation.  
 
Siglecs as target of cancer therapy 
The identification of siglec-2 and siglec-3 as markers of acute myeloid leukemia (AML) and B 
cell lymphomas raised interest in potential immunotherapy (Ball, 1988, Drexler, 1987, Ziegler-
Heitbrock et al., 1986). Anti-Siglec-2 and siglec-3 specific antibodies were conjugated with 
variety of toxins and such immunotoxins has been targeted in several autoimmune diseases and 
hematological malignancies (reviewed in (Crocker et al., 2012, Jandus et al., 2011, O'Reilly and 
Paulson, 2009). Siglec-2 (CD22) expression is the majority of B cell lineage of acute 
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lymphoblastic leukemias was identified as a useful target for cell-depletion therapy (Jain et al., 
2014). Inotuzumab ozogamicin is an immunotoxin comprised of a humanized IgG4 monoclonal 
antibody covalently linked to calecheamicin (CMC-544). CMC-544 was active against B-cell 
tumors in preclinical models and has been evaluated in phase I study for patients with B-cell 
lineage acute lymphoblastic leukemia (ALL) (Kantarjian et al., 2013). Inotuzumab ozogamicin 
used as a single therapy in patients with refractory-relapsed ALL showed positive results. 
The immunotoxin gemetuzumab ozogmizin (OG, Mylotarg; Wyeth, Madison, NJ), which 
consists of a humanized anti-CD33 (siglec-3) murine antibody linked to calicheamicin, was 
approved by the FDA for treatment of CD33+ AML patients. Binding and endocytosis of the 
conjugate resulted in the intracellular release of the toxin causing cell death of CD33+ cells 
(Jandus et al., 2011, O'Reilly and Paulson, 2009). However the drug is off the market since 2010 
because the key phase III trial (South West Oncology Group Study S0106) in which GO was 
combined with induction chemotherapy failed to improve disease-free survival and higher fatal 
induction toxicity rate compared to chemotherapy alone occurred (Petersdorf et al., 2013). Recent 
studies using lower or fractionated dose of GO suggest that GO may still improve survival of 
distinct subsets of AML patients, particularly patients with favorable cytogenetics (Gasiorowski 
et al., 2013). New approaches with humanized CD33 antibody conjugated to synthetic DNA 
crosslinking pyrrolobenzodiazepine (SGN-CD33A) have been developed and revealed promising 
effectiveness in animal models (Kung Sutherland et al., 2013). SGN-CD33A is now currently 
being tested in a phase I trial (ClinicalTrials.gov: NCT01902329). 
 
Galectins 
In contrast to siglecs and selectins, which are mostly cell surface-bound receptors, galectins are 
soluble immunomodulatory lectins (Rabinovich and Toscano, 2009). Galectins bind to galactose 
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that is either β1,3- or β1,4-linked to N-acetylglucosamine, a common disaccharide found both on 
N- and O-linked glycans and glycolipids. Galectins act both intracellularly by modulating 
signaling pathways and extracellularly as regulatory receptors (Rabinovich et al., 2012). Up to 
date the galectin family consists of 15 members which are classified into three groups based on 
structural differences: prototype galectins (Galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15) 
having one carbohydrate recognition domain (CRD), tandem repeat-type galectins (Galectin-4, -
6, -8, -9, and -12) having two CRDs and the single member Galectin-3 which has one CRD 
connected to a non-lectin N-terminal region responsible for oligomerization (Rabinovich et al., 
2012). Galectins are expressed by various cell types including epithelial and immune cells, but 
their expression is altered during progression of colon, breast, lung, pancreatic, head and neck 
and cervical cancers (Ito et al., 2012, Liu and Rabinovich, 2005). Many studies indicate that 
cancer-associated galectins could regulate cancer cell proliferation, signaling, adhesion, invasion 
and metastasis (Califice et al., 2004, Liu and Rabinovich, 2005, Takenaka et al., 2004). Galectin-
1 and Galectin-3 were most intensively studied in context of cancer.  
Galectin-1 
Accumulating evidence indicates that tumor-derived Galectin-1 contributes to 
immunosuppressive activity in different tumors, including lung and pancreatic carcinoma, 
melanoma and neuroblastoma (Banh et al., 2011, Ito et al., 2012, Rubinstein et al., 2004, Tang et 
al., 2012). It has been shown that Galectin-1 binding to T cells through N- and O-linked glycans 
on CD43 or CD45 mucins induces apoptosis of activated T cells (Hernandez et al., 2006, Nguyen 
et al., 2001). Galectin-1 expression by melanoma cells induced apoptosis of tumor-specific 
effector T cells, and Galectin-1 inhibition allowed generation of a tumor-specific T1 response 
(Rubinstein et al., 2004). Modification of cell surface glycosylation affects glycan pattern on T 
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cells and thereby changes Galectin-1 binding. Enhanced expression of α2,6-sialyltransferase-1 
(ST6Gal1) selectively modified N-glycans on CD45 and thereby inhibited Galectin-1 binding 
(Amano et al., 2003). How Galectin-1 contributes to immune suppression in tumors has been 
delineated in lung cancer (Kuo et al., 2011). High expression of Galectin-1 in lung cancer cell 
lines, as well as in human tumor tissues, alters the phenotype of monocyte-derived dendritic cells 
and impairs T cell response, concomitant with increased presence of regulatory T cells (Tregs). 
The regulatory effect of Galectin-1 is mediated by increased expression of IL-10 in monocytes 
thereby inducing a Th2-dominant cytokine profile. The enhanced infiltration of CD11c+ dendritic 
cells in human lung cancer samples has been recapitulated in a mouse model, which was 
completely omitted after transplantation of Galectin-1 silenced tumor cells. In another study the 
amount of Galectin-1 positive cells correlated with the tumor grade in human breast cancer 
(Dalotto-Moreno et al., 2013). Silencing of Galectin-1 in a metastatic murine mammary tumor 
led to a reduction of tumor growth and lung metastasis with a concomitant reduction in 
infiltrating regulatory T cells. 
Experimental evidence also suggests that Galectin-1 expressed on various tumor cell types 
including hepatocellular carcinoma, melanoma, ovarian and prostate cancer cells mediates tumor 
cell adhesion to the extracellular matrix (Perillo et al., 1998, van den Brule et al., 2003). In 
addition, Galectin-1 mediated attachment of cancer cells to the extracellular matrix and 
endothelial cells through binding to CD44 and CD326 on murine breast and colon cancer cells 
(Ito et al., 2012). Galectin-1 might also be involved in formation of platelet-cancer cell 
complexes since it was shown to activate platelets (Pacienza et al., 2008). Murine breast, colon 
and Lewis lung cancer cells with silenced Galectin-1 showed decreased lung metastasis which 
was associated with increased T cell numbers and reduced angiogenesis (Banh et al., 2011, Ito et 
al., 2012). Taken together, tumor-derived Galectin-1 exerts its immunosuppressive function 
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through binding to endogenous (non-tumor-derived) glycans and thereby contributes to cancer 
progression.  
 
Galectin-3 
There is accumulating evidence that the cancer-associated T, Tn and sTn structures promote 
metastasis through binding to Galectin-3. Galectin-3 expression is also increased in patient sera 
of several cancer types and associated with increased risk of metastasis (Iurisci et al., 2000, 
Vereecken et al., 2006). For instance, T antigen expression by breast and prostate cancer cells 
facilitated interactions with cancer-associated Galectin-3 or with endothelial associated Galectin-
3 (Glinsky et al., 2001, Khaldoyanidi et al., 2003, Yu et al., 2007, Zhao et al., 2010). These 
interactions lead to homotypic aggregation of cancer cells, which protects cancer cells from 
apoptosis induced by the lack of adhesion to the extracellular matrix (Zhao et al., 2010). In 
addition, cancer cell-associated T antigens can induce Galectin-3 expression on the endothelium 
which enabled cancer-endothelium adhesion (Glinsky et al., 2001). Another study has shown that 
lysosomal-associated membrane protein-1 (LAMP-1) on highly metastatic melanoma cells carries 
N-acetyllactosaminyl structures which are recognized by Galectin-3 on lung endothelial cells 
suggesting that lung endothelial galectin-3 can serve as anchor for LAMP-1 expressing tumor 
cells in the circulation (Krishnan et al., 2005).  
A characteristic feature of galectins is the induction of complex formation by cross-linking 
glycoproteins, which can form multimers “lattice” microdomain (Rabinovich and Toscano, 
2009). Complex N-glycans are formed by GnT5 modification of N-glycans that are the ligands 
for Galectin-3 (Lau et al., 2007). Expression of GnT5 has long been implicated in tumor 
progression and metastasis (Dennis et al., 1987). Besides, the absence of GnT5 delayed tumor 
formation and suppressed metastasis (Granovsky et al., 2000). Accordingly, up-regulated GnT5 
18 
 
expression has been observed in various human cancers (Kobata and Amano, 2005, Lau and 
Dennis, 2008); and the ectopic expression of the GnT-V in multiple epithelial cells resulted in 
increased cell motility, tumor formation and enhanced metastasis (Chen et al., 1998, Demetriou et 
al., 1995). Furthermore, GnT5-dependent modifications of tyrosine kinase receptors such as EGF, 
TGF-β, IGFR and PDGF enhanced affinity to galectin-3 and thereby prolonged their cell surface 
expression (Lajoie et al., 2007, Partridge et al., 2004). Galectin-3-induced lattice formation 
prevented the surface clearance of receptors by clathrin-dependent endocytosis and enabled 
interaction with inhibitory caveolin-1 domains.  
Branched O-glycans with poly-N-acetyllactosamine structures are recognized by Galectin-3 
(Tsuboi et al., 2011). In C2GnT1-expressing bladder tumor cells core 2 O-glycans present on 
MHC class I-related chain A are bound to Galectin-3 that reduced the affinity for the activating 
NK cell receptors NKG2D, thereby impairing NK cell function and antitumor activity.   
Recent findings suggest that Galectin-3 also regulates dynamics of N-cadherin and the raft 
marker ganglioside GM1 (Boscher et al., 2011). Accumulation of N-cadherin and GM1 at cell-
cell junctions destabilized cell-cell junctions and thereby contributed to tumor cell migration. N-
glycans on α5β1 integrin are important for their proper binding to fibronectin (Veiga et al., 1995, 
Zheng et al., 1994). Increased GnT5 mediated β1,6-branching reduces cell surface clustering of 
α5β1 integrin specifically of the β1 subunit resulting in a less adhesive phenotype due to reduced 
adhesion to fibronectin and modulates fibronectin matrix remodeling in tumors (Guo et al., 2002, 
Lagana et al., 2006). Thus Galectin-3 lattice formation provides another mechanism how altered 
glycosylation contributes to the malignant and invasive phenotype of tumor cells (Boscher et al., 
2011).   
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Selectins 
Selectins are vascular cell adhesion molecules that belong to a family of C-type lectins which 
facilitate the initial attachment of leukocytes to the endothelium during the process of leukocyte 
extravasation. The selectin family consists of L-, E-, and P-selectin which share around 50% 
sequence homology in their C-type lectin domain (Kansas, 1996). L-selectin (LECAM-1, 
CD62L) is constitutively expressed on almost all hematopoietic cell types including myeloid 
cells, naïve and some activated memory T-cells (Kansas, 1996) and enables adhesion of 
leukocytes to the activated endothelium or in high endothelial venules of the peripheral lymph 
nodes (Guyer et al., 1996, Sperandio et al., 2003). E-selectin (ELAM-1, CD62E) is exclusively 
displayed on endothelial cells which requires de novo expression in response to inflammatory 
stimuli such as TNF-α and Il-1β. However, skin and parts of the bone marrow microvasculature 
have been shown to constitutively express certain E-selectin levels (Sipkins et al., 2005). On 
contrary, P-selectin (PADGEM, CD62P) is stored in alpha-granules of platelets as well as in 
Weibel-Pallade bodies of endothelial cells and can be rapidly mobilized to the cell surface upon 
activation of platelets or the endothelia. E- and P-selectin bind to ligands on myeloid cells (Lenter 
et al., 1994), certain types of lymphocytes (Kansas, 1996) but also to several types of tumor cells 
(Burdick et al., 2003, Kim et al., 1999, McCarty et al., 2000). Selectins are the most-studied 
lectins in cancer biology which promote cell-cell interaction with tumor cells and their 
microenvironment (Läubli and Borsig, 2010). All three selectins have been shown to contribute 
to tumor dissemination and specifically facilitate processes when the tumor cells are in the 
circulation.   
Selectin ligand expression correlates with cancer progression 
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There is compelling clinical and experimental evidence that overexpression of tetrasaccharides 
sLex and sLea correlates with poor prognosis due to enhanced metastatic phenotype in a number 
of cancer types, including colon, gastric, prostate, renal, pancreatic and lung cancer (Jorgensen et 
al., 1995, Nakamori et al., 1993, Ogawa et al., 1996, Renkonen et al., 1997, Takahashi et al., 
2001, Tatsumi et al., 1998, Tozawa et al., 2005). Enhanced expression of sLex/a on cancer cells 
correlated with increased ability to adhere to E-selectin or to the activated endothelial cells and 
stromal cells in vitro (Burdick et al., 2003, Inaba et al., 2003, Mannori et al., 1995, St Hill et al., 
2005). Furthermore, high cell surface expression levels of sLex were linked to enhanced 
metastatic activity in various experimental metastasis models using human carcinoma cells 
compared to lower or minimal sLex expression (Barthel et al., 2009, Izumi et al., 1995, Weston et 
al., 1999).  
The minimal recognition motif for all three selectins are tetrasaccharides sLex/a (Figure 2) (Rosen 
and Bertozzi, 1994). SLex are terminal structures of N-or O-linked glycans attached to 
glycoproteins and glycolipids displayed by most circulating leukocytes and endothelial cells 
whereas sLea is detected on some epithelial cells but mostly on various tumor cells (Kannagi, 
1997, Kim and Varki, 1997, Kim et al., 1996). The four glycosyltransferases N-
acetylglucosaminyltransferase, β1,4-galactosyltransferase, α2,3-sialyltransferase and α1,3-
fucosyltransferase-7 are responsible for synthesis of sialyl-Lewisa/x structures on cells of the 
hematopoietic system (Rosen and Bertozzi, 1994, Sperandio et al., 2009). Efficient selectin 
binding to carbohydrates usually requires a glycoprotein scaffold that facilitates the presentation 
of selectin ligands in clusters (Varki, 1997). One of the best characterized ligands for all three 
selectins is the P-selectin glycoprotein ligand-1 (PSGL-1), which is concentrated on the tips of 
microvilli on leukocyte surface (McEver, 2002). To the most common mucins carrying selectin 
ligands that are associated with cancer progression belong MUC1, MUC2, MUC4 and MUC16 
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(Baldus et al., 2002, Chaturvedi et al., 2008, Chen et al., 2012, Hollingsworth and Swanson, 
2004). Apart from mucins, several other selectin ligand carriers on tumor cells have been 
identified that includes CD24, CD44, death-receptor 3, E-selectin ligand-1, PSGL-1 and 
podocalyxin-like protein and this list is by far not complete (Aigner et al., 1997, Burdick et al., 
2006, Dimitroff et al., 2005, Gout et al., 2006, Thomas et al., 2009). Several of these ligands are 
also expressed on tumor cells and are associated with cancer progression. For instance, CD44 
glycoproteins exist in several isoforms and are expressed on epithelial and endothelial cells as 
well as on multiple cancer cell types such as gastric, colorectal, pancreatic and lung cancer 
(Heider et al., 1993, Penno et al., 1994, Rall and Rustgi, 1995). The aberrant expression of CD44 
in colorectal carcinoma cells correlated with increased metastatic potential in vivo (Harada et al., 
2001, Reeder et al., 1998). Based on flow-based adhesion assays in vitro, CD44v on human colon 
carcinoma cells binds to P-, E-, and L-selectin (Hanley et al., 2005, Hanley et al., 2006). The 
majority of selectin ligands are presented on mucins, but they can be found equally functional 
also on N-linked glycans or glycolipids. Finally, P- and L-selectins also bind to heparin, heparan 
sulfate and sulfated glycolipids, which also indicates certain flexibility in ligand recognition 
(Läubli and Borsig, 2010, Varki, 1997). In addition, chondroitin sulfate glycosaminoglycans (CS-
GAGs) on breast cancer cells were identified to serve as a P-selectin ligand that is associated with 
breast cancer metastasis (Cooney et al., 2011). Despite the large variety of glycans, tumor cells 
express sialylated, fucosylated molecules, mostly on mucins which are also recognized by 
selectins (Kaytes and Geng, 1998, Kim et al., 1999, Mannori et al., 1995, McCarty et al., 2000, 
Stone and Wagner, 1993). 
Increased expression of sLex/a in tumor cells has been attributed to elevated levels of α1,3-
fucosyltransferase-7 (FUT7) which has also been shown to correspond with increased 
malignancy in lung cancer patients (Ogawa et al., 1996). In addition, overexpression of α1,3-
22 
 
fucosyltransferase-3 and -6 in metastatic prostate cancer cells correlated with higher sLex levels 
and more metastasis that was dependent on E-selectin-mediated recruitment to distant sites 
(Barthel et al., 2009, Li et al., 2013). Genes encoding for FUT3, FUT4 and ST3GAL6 enzymes 
that are involved in sLex synthesis were significantly increased in breast cancers and correlated 
with metastasis to the bone where sLex receptor E-selectin is constitutively expressed (Julien et 
al., 2011). Inflammatory cytokines might also be involved in sLex production. TNF-α enhanced 
motility and invasion properties of prostatic cancer cells were associated with selective 
upregulation of genes related to sLex synthesis (Radhakrishnan et al., 2011). Studies analyzing 
prostate and pancreatic cancer cell homing into bone showed that E-selectin-mediated adhesion is 
dependent on enhanced α1,3-fucosyltransferase, FUT3, FUT6 and FUT7 activity (Barthel et al., 
2013, Yin et al., 2010). Consequently, downregulation of α1,3-fucosyltransferase activity 
dramatically reduced prostate cancer incidence. However, there is also the possibility that 
selectin-mediated activation of either tumor cells or the tumor microenvironment further promote 
inflammation that is a hallmark of cancer progression. 
 
P-selectin 
The association between circulating cancer cells, platelets, and formation of tumor microemboli 
is widely accepted (Borsig, 2008, Gay and Felding-Habermann, 2011, Honn et al., 1992, 
Karpatkin and Pearlstein, 1981). Many studies showed that platelets enhance hematogenous 
dissemination, intravascular tumor cell survival and metastasis (Borsig et al., 2001, Camerer et 
al., 2004, Nieswandt et al., 1999, Palumbo et al., 2005). However, the major mechanism of 
platelet-adhesion to tumor cells has been found to be mediated by platelet P-selectin (Kim et al., 
1998). Platelet-tumor cell interactions were significantly reduced in P-selectin deficient mice, and 
consequently attenuation of metastasis was observed. Enzymatic removal of carcinoma mucins 
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carrying selectin ligands from tumor cells prior to tail vein injection resulted in attenuated 
metastasis comparable to the absence of P-selectin (Borsig et al., 2001, Kim et al., 1999). In 
addition, endothelial P-selectin-mediated interactions also contributed to metastasis indicating 
that both platelet and endothelial P-selectin promote early events during tissues colonization 
(Borsig et al., 2002, Ludwig et al., 2004). In another study was showed that platelets promote 
lung metastasis of B16F1 melanoma and 4T1.2 breast cancer cells (Coupland et al., 2012). 
Platelet depletion resulted in a significant reduction of lung metastasis when compared to NK cell 
depleted animals, indicating an additional pro-metastatic function of platelets. These findings are 
in agreement with a direct effect of platelet-tumor cell interactions that promotes the metastatic 
behavior of tumor cells (Labelle et al., 2011). Taken together, P-selectin-mediated interactions 
significantly contribute to the early steps of metastasis when tumor cells are in circulation.  
 
L-selectin 
L-selectin binds to a variety of tumor cells and contributes to metastasis (Jadhav et al., 2001, 
Mannori et al., 1995).  Intravenous injection of human and murine tumor cells in L-selectin 
deficient mice resulted in reduced recruitment of leukocytes and subsequently attenuated 
metastasis that confirmed the active role of L-selectin-mediated interaction in this process 
(Borsig et al., 2002, Läubli et al., 2006). Metastasis was further attenuated in P- and L-selectin 
double deficient mice providing evidence that both selectins synergistically contribute to 
metastasis (Borsig et al., 2002). In addition, the enhanced expression of selectin ligands around 
the metastatic tumor cells was detected with L-selectin chimera, which correlated with the 
recruitment of leukocytes (Läubli et al., 2006). These findings indicated that L-selectin is either 
responsible for recruitment of leukocytes or their interactions within the metastatic 
microenvironment.  Enhanced presence of inflammatory cells, primarily myeloid-derived cells, in 
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the tumor microenvironment is usually associated with tumor growth and metastatic 
dissemination (Joyce and Pollard, 2009, Mantovani et al., 2008). Thus, L-selectin represents a 
potential facilitator of myeloid cell recruitment to metastatic sites and thereby promotes early 
steps of metastasis, e.g. tumor cell extravasation (Läubli et al., 2009, Läubli et al., 2006). During 
inflammation, leukocyte interaction with the endothelium results in induced vascular 
permeability. However, whether L-selectin promotes metastasis through a direct engagement 
with selectin ligands on tumor cells or rather mimics inflammatory-like reaction accompanying 
the process of tumor cell seeding in distant organs remains to be determined.   
E-selectin  
E-selectin has been the first selectin intensively studied in context of metastasis (Läubli and 
Borsig, 2010, Witz, 2008). The original hypothesis was that E-selectin mediates metastatic 
dissemination to distant organs through binding to ligands on tumor cells, similarly to leukocyte 
adhesion during inflammation (Kannagi, 1997). Numerous studies provided evidence that tumor 
cells expressing selectin ligands adhere to activated endothelium under flow condition in vitro 
(Burdick et al., 2003, Dimitroff et al., 2005, St Hill et al., 2005). While different E-selectin 
ligands were linked to enhanced metastasis, the majority of them belong to the mucin type 
molecules.  Despite the observation of increased primary tumor growth in selectin deficient mice, 
which seems to be linked to reduced anti-tumorigenic infiltration of immune cells (Taverna et al., 
2004), there is accumulating evidence that E-selectin promotes cancer metastasis in animal 
models. Enhanced E-selectin expression was observed in the liver during metastatic colonization 
and the down-regulation of E-selectin resulted in attenuation of metastasis (Laferriere et al., 
2001, Tremblay et al., 2006). Metastasis was redirected to the E-selectin overexpressing liver 
using experimental lung metastasis model, which provided direct evidence for involvement of E-
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selectin in facilitation of tumor cell seeding (Biancone et al., 1996). Accordingly, experimental 
liver metastasis of human colon carcinoma cells was also E-selectin dependent (Brodt et al., 
1997). However, experimental lung metastasis of human colon adenocarcinoma cells remained 
unchanged in E-selectin deficient mice (Läubli and Borsig, 2010). On contrary, spontaneous 
metastasis of human breast cancer cells to the lungs was significantly attenuated in E-selectin-
deficient mice (Stubke et al., 2012). Interestingly Hiratsuka et al showed that factors secreted 
from primary tumors can activate endothelial focal adhesion kinase and E-selectin expression in 
the lung vasculature and thereby induce the formation of permissible sites for metastasis 
(Hiratsuka et al., 2011). Enhanced homing of metastatic tumor cells to these sites was observed 
and was associated with metastasis. These observations indicate that primary tumors can actively 
form a distant metastatic niche and upregulate expression of cell adhesion molecules involved in 
tumor cell-endothelial interactions. In conclusion, there is convincing evidence that endothelial 
E-selectin facilitates metastasis by enabling tumor cell adhesion to vasculature. Nevertheless, the 
exact mechanism of E-selectin facilitation of metastasis remains to be defined.  
Carcinoma mucins as initiators of cancer-related prothrombotic activity 
Altered cancer glycosylation is not reflected only on cell surface molecules, but aberrantly 
glycosylated proteins are detected in the circulation (Kannagi et al., 2010). Antibodies raised 
against tumor cells, were shown to specifically recognize glycan structures, e.g. sLea which are 
currently used for cancer diagnostics (Hollingsworth and Swanson, 2004). The presence of 
carcinoma mucins (e.g. CA-125, CA19-9), which are shedded from tumors, are routinely used as 
serum tumor markers in diagnosis of cancer. Besides, efficient binding of recombinant soluble 
selectin to carcinoma mucins has been observed (Kim et al., 1999, Wahrenbrock et al., 2003). 
Increased thromboembolism is a recognized complication in various carcinomas, particularly 
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mucinous carcinomas, however; there are several pathologic mechanisms likely to be involved 
(Varki, 2007). Idiopathic thromboembolism, which is frequently associated with occult 
carcinomas, belongs to the Trousseau syndrome. Recent studies provided evidence that 
intravenous injection of carcinoma mucins carrying selectin ligands into mice resulted in 
generation of platelet-rich microthrombi (Wahrenbrock et al., 2003). This pathology was 
markedly diminished in P-selectin or L-selectin deficient mice. Interestingly, carcinoma mucins 
could not activate platelets and thereby could not generate microthrombi in mice lacking PSGL-1 
(Shao et al., 2011). Carcinoma mucins initiated thrombosis only in the presence of platelets that 
induced release of cathepsin G from neutrophils through a selectin-dependent, reciprocal 
activation of neutrophils and platelets. Taken together, carcinoma mucins carrying selectin 
ligands in blood circulation may serve as initiators of thrombi formation observed in cancer 
patients.  
Selectins shape the metastatic microenvironment 
There is accumulating evidence that selectins facilitates heterotypic interactions between tumor 
cells and blood components, including the endothelium and thereby promote tumor cell seeding, 
survival and extravasation (Gil-Bernabe et al., 2012, Labelle and Hynes, 2012, Läubli and Borsig, 
2010). When circulating tumor cells arrest in the microvasculature of distant organs, early on 
markers of endothelial cell activation and inflammation, including E-selectin, were upregulated in 
experimental lung and liver metastasis models (Ferjancic et al., 2013, Khatib et al., 1999, Läubli 
and Borsig, 2010, Matsuo et al., 2006, Vidal-Vanaclocha et al., 2000). Enhanced E-selectin 
expression was detected also in the metastatic lungs using a spontaneous metastatic model with 
Lewis lung carcinoma (Hiratsuka et al., 2011, Läubli and Borsig, 2010). Consequently, inhibition 
of endothelial activation and/or E-selectin function attenuated metastasis (Kobayashi et al., 2000, 
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Matsuo et al., 2006).  Endothelial activation caused by factors derived from primary tumor or 
from arrested tumors in the vasculature promoted selectin-mediated interactions and formation of 
a permissive microenvironment within the vasculature prior to tumor cell extravasation (Borsig et 
al., 2002, Läubli et al., 2009, Läubli et al., 2006). Tumor cell glycan-induced and P-selectin 
dependent endothelial activation resulted in enhanced expression of E-selectin and vascular cell 
adhesion molecule 1 (VCAM-1) and promoted lung colonization and metastasis (Läubli et al., 
2009). In addition, elevated production of chemokine CCL5 contributed to the recruitment of 
monocytes. Accordingly, endothelial VCAM-1 expression was induced by tumor-cell embolus 
that resulted in increased recruitment of myeloid cells supporting metastasis (Ferjancic et al., 
2013). Recruitment of inflammatory cells, especially myeloid-derived cells, is strongly associated 
with enhanced metastatic colonization that is at least partially dependent on L-selectin (Hoos et 
al., 2013, Läubli et al., 2009, Läubli et al., 2006, Lu and Kang, 2009, Qian et al., 2009, Wolf et 
al., 2012). Taken together, the selectin-mediated interactions play a critical role during the 
establishment of metastasis that is co-initiated by aberrant glycans on tumor cells in circulation. 
Whether tumor glycans only initiate the inflammatory-like cascade leading to metastasis or have 
further function in shaping this process remains to be defined. 
 
Conclusions and perspectives 
Cancer-associated aberrant glycosylation has been identified in virtually every type of cancer. 
Expression of cancer-specific glycan epitopes represents a great opportunity to explore them for 
diagnostics and potentially specific targeting of tumors. Considering that genes only indirectly 
regulate glycan formation, it is still puzzling that glycan epitopes has been consistently validated 
as cancer markers. Based on the broad expression and high specificity for cancer tissues, T 
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antigen is currently explored as a potential target for development of cancer diagnostics and 
immunotherapeutics (Fujita-Yamaguchi, 2013, Ito et al., 2012). Since the expression of sTn 
antigens on the majority of tumors correlated with poor prognosis, the sTn antigen has become a 
target for cancer vaccine (Cao et al., 1996, Itzkowitz et al., 1989). Administration of sTn 
disaccharide conjugate to highly immunogenic protein induced antibodies against sTn and 
showed protective effects in a mouse model of breast cancer (Julien et al., 2009). Although a 
randomized phase III clinical trial using the same sTn vaccine did not improve overall survival, 
patients with high titer against the sTn had significantly prolonged overall survival (Ibrahim et 
al., 2013). 
 
The accumulating knowledge about the function of lectin-tumor cell glycan interactions in cancer 
will open ways for new approaches to interfere with cancer progression. However, the 
exploitation of such therapeutic opportunities requires a comprehensive knowledge about the 
underlying mechanisms of lectin-mediated interactions. Nevertheless, the role of selectins in 
cancer progression has been extensively investigated in number of preclinical models and the 
mechanism at least partially characterized (Läubli and Borsig, 2010). Clearly, further studies in 
the exact mechanism of action are still required, but selectin inhibition in cancer has been 
inadvertently clinically tested in cancer patients treated with antithrombotic therapies (Borsig et 
al., 2007). Unfractionated heparin as well as low molecular weight heparin has a strong P- and L-
selectin inhibitory activity at clinically relevant concentrations. Retrospective analysis of clinical 
studies revealed that apart from antithrombotic activity, heparin improved survival of cancer 
patients especially in patients with early stage disease. Still, prospective and well-designed 
clinical study remains to be performed. Similarly, development of highly specific ligand probes 
for siglecs (e.g. Siglec-2) revealed the ability to target siglec-expressing cells (O'Reilly and 
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Paulson, 2009). Further investigations are required for deciding whether glycan-specific targeting 
of lectins involved in cancer modulation (e.g. siglec, selectins or galectins) or rather development 
of glycan-specific targeting of tumor cells represents the right approach for the treatment of 
cancer. The cell surface presentation of unique glycan epitopes makes them an “ideal” candidate 
for targeting since they are both specific and therapeutically accessible. Future studies need to 
validate the therapeutic potential in clinically relevant experimental models prior to clinical 
evaluation. 
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 Figure legends 
Figure 1. Biosynthesis of O-glycans. O-glycan synthesis is initiated by linking of GalNAc to the 
protein at Ser or Thr residue. The simplest O-glycan Tn antigen can be further converted to core 
1 structure (T antigen) by β1,3 galactose extension; core 3 structure by addition of β1,3-GlcNAc. 
During cancer increased expression (green arrow) of sialyltransferases with concomitant reduced 
expression (red arrow) of core 1 GalT and core 3 GlcNAcT leads to increased formation of sialyl-
Tn and sialyl-T antigens. Core 1 structure is further branched by C2GnT1 to form core 2 that can 
be further modified to poly-Nacetyllactosamine structures carrying sialyl Lewisx/a.  
 
Figure 2. Formation of Lewis antigens. Terminal GlcNAc residues, particularly on core 2 
structures, are further extended by addition of β1,4 galactose, for Lewisx epitope, and β1,3 
galactose, for Lewisa epitope. This is further followed by the addition of α2,3-linked sialic acid to  
Gal by ST3Gal enzymes and finalized by the addition of α1,3-linked fucose for sLex and α1,4-
linked fucose for the sLea antigen. FUT3 finalized the synthesis of Lea antigen, while FUT6, 
FUT7 were shown to finalize Lex epitopes. 
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Table 1. Common glycan alterations on carcinoma cells and their effect on lectin recognition. 
Structural change Carriers Biosynthetic basis of structural change 
Potential lectin 
partners References 
Increased β1,6-branching 
(N-linked) N-glycans  
N-glycans 
e.g. β integrin  
Increased GnT5 
Galectins 
Siglecs 
(Guo et al., 2007, Lagana 
et al., 2006) 
Increased α2,6-sialylation Increased ST6Gal1 sialyltransferase (Seales et al., 2005) 
General increase in 
sialylation 
Mucins 
N-glycans 
Increased sialyltransferase 
activity 
Selectins, Siglecs, 
Galectins 
(Dall'Olio et al., 1989, 
Gessner et al., 1993) 
Increased sialyl-Lewisx/a Mucins  
Increased FUT7, FUT3, FUT6, 
ST3Gal6 Selectins 
(Barthel et al., 2009, 
Julien et al., 2011, Koike 
et al., 2004, Ogawa et al., 
1996, Yin et al., 2010). 
Decreased di-sialyl-Lewisx/a Mucins, glycolipids  
Decreased ST6GalNAc6 
GlcNAc6ST1 
Selectins 
Reduced siglecs 
binding 
(Miyazaki et al., 2004, 
Tsuchida et al., 2003) 
(Nudelman et al., 1986) 
Increased Tn epitopes 
Mucins (e.g. MUC1),  
CD44, β1 integrin, 
osteopontin 
 
Downregulated T-synthase 
activity due to Cosmc 
mutations 
Galectins (Ju et al., 2008) 
Increased sialyl-Tn epitopes Increased ST6GalNAc1 expression 
Siglecs 
Galectins 
(Julien et al., 2001, Ozaki 
et al., 2012) 
Increased T antigen (core 1 
structure) 
Decreased C2GnT2 
Enhanced availability of UDP-
galactose 
Galectins 
(Brockhausen et al., 1995, 
Dalziel et al., 2001) 
(Kumamoto et al., 2001) 
Increased sialyl-T antigens Increased levels of α2,3-sialyltransferase (ST3Gal1) 
Galectins 
Siglecs 
(Burchell et al., 1999, 
Dalziel et al., 2001, Picco 
et al., 2010, Schneider et 
al., 2001) 
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